Complete and Accurate Records. Franchisee shall keep complete and accurate books of account and records of its business and operations under and in connection with this Agreement.
Complete and Accurate Records. University maintain records of the status and progress of the Research as required by the applicable Project Proposal with sufficient detail for use in reports to regulatory agencies.
Complete and Accurate Records. [NAVY COLLABORATOR] PI shall maintain complete and accurate records of the status and progress of the Cooperative Work and shall provide such information to [NON-NAVY COLLABORATOR] upon request. [NAVY COLLABORATOR] PI shall promptly complete, and allow [NON-NAVY COLLABORATOR] access to, [NON-NAVY COLLABORATOR]-supplied case report forms for all Study Patients. Upon [NON-NAVY COLLABORATOR]’s request, [NAVY COLLABORATOR] PI shall correct any case report form errors and/or omissions by promptly submitting [NON-NAVY COLLABORATOR]-supplied forms for resolving document discrepancies. At all times [NON-NAVY COLLABORATOR] shall remain the sole owner of the case report forms and document discrepancy resolution forms.
Complete and Accurate Records. The information set forth in the books and records of the Business, which have been made available to the Purchasers, is correct and complete in all material respects and have been maintained, in all material respects, in accordance with sound business practices.
Complete and Accurate Records. Site shall, and shall cause PI and each Study Staff Member to, prepare, maintain and retain complete, current, accurate, organized and legible Study Data (as defined below) as required by the Protocol and in a manner acceptable for the collection of data for submission to, or review by, any national, supranational or other governmental body having legal authority with respect to the Drug (each, a “Regulatory Authority”), including the US Food and Drug Administration or any successor agency thereto (“FDA”), and in full compliance with the Protocol and Law. “Study Data” means all laboratory and clinical data, primary and summary, that are generated with respect to the Study, including case report forms, safety information, informed consent forms and PI’s study notebooks, excluding any original Subject medical records that are considered “Source Documents” (as defined by International Conference on Harmonization (ICH) Guidance E6 “Good Clinical Practice”). (b)
Complete and Accurate Records. Institution will keep complete and accurate records of the status and progress of the Clinical Trial as required by the Protocol and, in any event, with sufficient detail for use in reports to regulatory agencies.
Complete and Accurate Records. Institution and Investigator will maintain complete and accurate records of the status and progress of the Study as required by the Protocol. Institution will create and maintain complete and up-to-date medical records of Study subjects. Investigator will adhere to the accuracy of the Study results as required by the Applicable Law. 4.2 Kompletní a přesné záznamy. Nemocnice a zkoušející budou vést kompletní a přesné záznamy o stavu a postupu studie, jak vyžaduje protokol. Nemocnice vytvoří a bude vést kompletní a aktuální lékařské záznamy týkající se subjektů studie. Zkoušející bude dbát na přesnost výsledků studie v souladu s požadavky rozhodného zákona.
Complete and Accurate Records. Institution and Investigator will maintain complete and accurate records of the status and progress of the Study as required by the Protocol, with sufficient detail for use in reports to regulatory agencies. Institution poskytovat služby jakékoli farmaceutické, zdravotnické nebo biotechnologické společnosti ani o takovém zákazu neuvažuje. Zdravotnické zařízení získalo a bude zachovávat všechna oprávnění a povolení, která jsou zákonem předepsána pro zdravotnické zařízení a zkoušejícího, aby mohli provádět studii dle této smlouvy. 2.5
Complete and Accurate Records. Institution and Principal Investigator shall maintain complete and accurate records of the status and progress of each study, all Study Patient information and all other data and information related to such study, including, but not limited to CRFs, Informed Consent Forms, Principal Investigator or Other Clinical Investigator's study notebook, Study Drug disposition forms and any documents deemed essential documents as defined by ICH Guideline for Good Clinical Practice Section 8, and shall provide such documents, data or information to Sponsor upon written request. Institution and Principal Investigator shall promptly complete, and allow Sponsor access to, Sponsor supplied CRFs for all Study Patients and any original source documents for all Study Patients. Institution and Principal Investigator shall comply with Sponsor's written instructions regarding the direct data flow process (in accordance with the applicable Study Documents). Upon Sponsor's written request, Institution, Personnel and Principal Investigator shall correct any CRF errors and/or omissions. At all times Sponsor shall remain the sole owner of all CRFs. Subject to the Confidentiality and Publication restrictions set forth in this Master Agreement, nothing herein, however, shall prevent Institution and Principal Investigator from using information or data, generated solely by Institution and/or Principal Investigator and provided to Sponsor hereunder, for non-commercial research and educational purposes of a state university. 2.10.2.
Complete and Accurate Records. The Site shall maintain complete and accurate records of the status and progress of the Study, all Subject information and all other data and information related to the Study, and shall provide such documents, data or information to Sponsor upon written request. The Institution shall promptly complete CRFs within five (5) business days of each Subject’s visit, and allow Sponsor or CRO access to, such CRFs for all Subjects and any original source documents for all Subjects. Upon Sponsor's request, Institution and Personnel shall correct any CRF errors and/or omissions. 2.6.
